| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.2 | 0.0 |
| Net income | -15.6 | -13.6 |
| EPS (diluted, $ a share) | $-0.12 | $-0.11 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: NAUT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Nautilus Biotechnology, Inc.: key numbers
- Share price
- $2.10Close, Nov 16
- Market cap
- $267M
- Shares outstanding
- 127.37MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Nautilus Biotechnology, Inc.
All →Nautilus Biotechnology Financial Results
Nautilus Biotechnology reported third quarter 2026 financial results, highlighting a net loss of $15.6 million on revenue of $0.2 million. The company noted progress on its proteoform assay pipeline and its Voyager platform, with plans for instrument availability in mid-2027. Subsequent to the quarter, the company was selected for an ARPA-H research consortium expected to provide up to $6 million in funding.
“The third quarter marked an important step in demonstrating the power and scalability of Iterative Mapping on our Voyager platform. Our seminal publication in Nature Methods highlights the unique biological insights that our technology can deliver. In addition, our proteoform expansion initiative is on-track, with early oncology assay results that demonstrate the performance we established with Tau is repeatable across additional targets. This repeatability is fundamental to our strategy of building a broad portfolio of proteoform assays, and the progress we are seeing reinforces our confidence in our technology, our development roadmap, and our planned instrument availability in the middle of 2027.”
Sujal Patel, CEO of Nautilus Biotechnology